Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · IEX Real-Time Price · USD
19.05
-0.45 (-2.33%)
Apr 23, 2024, 1:34 PM EDT - Market open

Kyverna Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021
Revenue
07.035.66
Revenue Growth (YoY)
-24.20%-
Gross Profit
07.035.66
Selling, General & Admin
12.488.016.15
Research & Development
49.9228.425.85
Operating Expenses
62.4136.4132
Operating Income
-62.41-29.38-26.35
Interest Expense / Income
0.190.070
Other Expense / Income
-2.23-0.560
Pretax Income
-60.37-28.89-26.35
Net Income
-60.37-28.89-26.35
Shares Outstanding (Basic)
100
Shares Outstanding (Diluted)
100
Shares Change
47.89%71.31%-
EPS (Basic)
-89.61-63.43-99.10
EPS (Diluted)
-89.61-63.43-99.10
Free Cash Flow
-53.03-36.88-23.44
Free Cash Flow Per Share
-78.72-80.97-88.17
Gross Margin
-100.00%100.00%
Operating Margin
--418.28%-465.81%
Profit Margin
--411.29%-465.88%
Free Cash Flow Margin
--525.00%-414.50%
EBITDA
-56.75-26.37-24.93
EBITDA Margin
--375.32%-440.81%
Depreciation & Amortization
3.432.461.42
EBIT
-60.18-28.83-26.35
EBIT Margin
--410.36%-465.82%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).